PureTech Reports Positive Phase 1b Data for LYT-200 in High-Risk MDS and R/R AML
PureTech Reports Positive Phase 1b Topline Data for LYT-200 in Relapsed/Refractory High-Risk MDS and AML PureTech Health plc, a hub-and-spoke biotherapeutics company focused on transforming scientific innovation into value and…
Veristat Announces Acquisition of Certara’s Regulatory and Medical Writing Business
Veristat to Acquire Certara’s Regulatory Affairs and Medical Writing Business Veristat, a science-first, full-service clinical research organization (CRO) and consultancy specializing in advancing complex therapies from early development through regulatory…
Synthekine Reports Promising STK-012 Activity in First-Line Non-Squamous NSCLC at AACR 2026
Synthekine Showcases Updated Clinical and Translational Data Highlighting Strong STK-012 Activity in First-Line Non-Squamous NSCLC at AACR 2026 Synthekine, a clinical-stage biotechnology firm focused on engineering precision cytokine therapeutics, has…
From IVF Innovation to Skin Longevity: AV Laboratories Turns Biotechnology into Breakthrough Skincare
AV Laboratories Transforms IVF Science into Breakthrough Skin Longevity Innovations AV Laboratories is positioning itself at the forefront of a new era in skincare by bringing together decades of advanced…
CareDx to Present Over 50 Abstracts, Including 16 Oral Sessions, at ISHLT 46th Annual Meeting
CareDx to Present Over 50 Abstracts, Including 16 Oral Presentations, at ISHLT 46th Annual Meeting CareDx, a leading precision medicine organization dedicated to advancing transplant care through innovative diagnostic and…
FDA Approves Merck’s Once-Daily IDVYNSO™ (doravirine/islatravir) Regimen
FDA Grants Approval to Merck’s Once-Daily IDVYNSO™ (doravirine/islatravir) Merck & Co. (NYSE: MRK), known as MSD outside the United States and Canada, has announced that the U.S. Food and Drug…
Pfizer Highlights Oncology Innovations and Next-Generation Pipeline at ASCO 2026
Pfizer Highlights Oncology Innovation and Advances in Next-Generation Pipeline at ASCO 2026 Pfizer Inc. (NYSE: PFE) has announced an extensive and data-rich presence at the American Society of Clinical Oncology…
Genentech’s Enspryng (Satralizumab) Cuts Relapse Risk by 68%, Showing Promise as First Treatment for MOGAD
Genentech’s Enspryng (Satralizumab) Cuts Relapse Risk by 68%, Showing Promise as a Potential First Treatment for MOGAD Genentech, a member of the Roche Group, has announced compelling new results from…
$15M Donor Funding Backs 62 Scientists Advancing Research in Alzheimer’s, Macular Degeneration, and Glaucoma
Donor Funding Drives $15M Initiative Supporting 62 Researchers Focused on Alzheimer’s, Macular Degeneration, and Glaucoma The BrightFocus Foundation has announced a major new investment of $15.2 million in research grants…
AHF Initiates Statewide Campaign Calling for Full Reinstatement of Florida’s AIDS Drug Assistance Program
AHF Initiates Statewide Campaign Calling for Full Reinstatement of Florida’s AIDS Drug Assistance Program The AIDS Healthcare Foundation (AHF) has launched a statewide public awareness campaign urging Ron DeSantis and…
Agenus to Present Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026
Agenus to Showcase Initial Phase 2 Botensilimab Results in Advanced Cutaneous Melanoma at ASCO 2026 Agenus Inc. (Nasdaq: AGEN), a clinical-stage immuno-oncology company focused on developing next-generation cancer immunotherapies, announced…
Real Time Medical Systems Expands Leadership, AI Solutions, and Partnerships at NAACOS Spring 2026
Real Time Medical Systems Highlights New Leadership, AI Solutions, and Expanded Partnership at NAACOS Spring 2026 Real Time Medical Systems (Real Time), a KLAS-rated and HITRUST R2 Certified leader in…